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Abstract 
Iron oxide nanoparticles are a useful diagnostic contrast agent and have great potential for 
therapeutic applications. Multiple emerging diagnostic and therapeutic applications and the 
numerous versatile parameters of the nanoparticle platform require a robust biological model 
for characterization and assessment. Here we investigate the use of iron oxide nanoparticles 
that target tumor vasculature, via the tumstatin peptide, in a novel three-dimensional tissue 
culture model. The developed tissue culture model more closely mimics the in vivo envi-
ronment with a leaky endothelium coating around a glioma tumor mass. Tumstatin-iron oxide 
nanoparticles showed penetration and selective targeting to endothelial cell coating on the 
tumor in the three-dimensional model, and had approximately 2 times greater uptake in vitro 
and 2.7 times tumor neo-vascularization inhibition. Tumstatin provides targeting and thera-
peutic capabilities to the iron oxide nanoparticle diagnostic contrast agent platform. And the 
novel endothelial cell-coated tumor model provides an in vitro microtissue environment to 
evaluate nanoparticles without moving into costly and time-consuming animal models. 
Key words: iron oxide nanoparticles, tumstatin, tumor penetration, multicellular tumor spheroids, 
theranostic, magnetic, nanoparticle, imaging, drug delivery, anti-angiogenesis 
Introduction 
Iron oxide nanoparticles (Fe3O4 NPs) hold great 
promise  for  realizing  early  tumor  diagnosis  and 
therapy,  as  well  as  simultaneous  monitoring  of  the 
therapeutic  response  [1,  2].  The  efficacy  of  imaging 
and therapy of these Fe3O4 NPs is typically evaluated 
by direct observation of their bio-distribution (espe-
cially  with  tumor  selectivity),  their  effects  on  the 
quality  of  life  (body  weight,  tumor  size,  etc.)  and 
longevity in animal models. Among many evaluation 
parameters, efficient transport of NPs into tumor tis-
sue  in  vivo  is  a  critical  aspect.  Ideally,  systemical-
ly-administered NPs can preferentially accumulate at 
tumor sites by the enhanced permeability and reten-
tion  (EPR)  effect,  thus  reducing  toxicity  to  normal 
tissue  [3].  However,  systemically-administered  NPs 
are often subject to a heterogeneous distribution in the 
tumor tissue and tend to concentrate near the tumor 
vasculature [4, 5]. This is a result from the increased 
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interstitial fluid pressure and the dense extracellular 
matrix  (ECM)  found  in  the  in  vivo  tumor  environ-
ment. As intervascular distances in tumors are rela-
tively large (>100 µm) [6], this undesired distribution 
limits the NP delivery and reduces their therapeutic 
efficacy [5]. 
Recently, there are emerging efforts to improve 
NP penetration via a multistage delivery system [7], 
or by grafting NPs with tumor penetration peptides 
[8]. Unfortunately, the verification of these platforms 
relies heavily on the in vivo models, which are costly, 
complicated, and time consuming. Given the numer-
ous possible NP designs, it is also unrealistic to test all 
types of NPs with in vivo models. Thus, an in vitro 
system that mimics solid tumor properties is highly 
desired.  Multicellular  tumor  spheroid  (MTS),  a 
three-dimensional  cluster  of  cancer  cells  grown  in 
vitro,  mimics  the  early  avascular  stage  of  tumor 
growth such as the presence of ECM and  diffusion 
gradients of nutrients and wastes [9, 10]. As a result, 
MTS can contain heterogeneous regions of tumor cell 
growth including a necrotic center with proliferating 
cells restricted to the outer rim of the MTS [11]. Their 
similarities  with  tumors  in  vivo  have  provided  an 
important  platform  for  nanotechnologists  to  screen 
various parameters of NPs and to identify those pa-
rameters with optimal tumor penetration [12-15]. For 
example, Goodman et al. examined the penetration of 
polystyrene NPs (20, 40, 100 or 200nm) in SiHa MTS 
(~500  um  diameter)  with  and  without  collagenase 
treatment [13, 14]. These pioneering studies revealed 
the  potential  of  MTS  as  a  cost-effective  and 
time-efficient  tool  for  examining  NP  penetration  in 
deep regions of tumors.  
However,  MTS  models  in  those  studies  were 
limited by their non-uniformity and simplicity. Spe-
cifically, MTS size in those studies are heterogeneous, 
ranging from a few millimeters to  hundreds of mi-
crometers,  which  presents  challenges  for  standardi-
zation  and  comparison  of  works  from  different  re-
searchers. Furthermore in  a biological environment, 
NPs  must  extravasate  through  a  leaky  vascular  en-
dothelium  before  penetrating  into  the  solid  tumor. 
This added parameter further decreases the transmi-
gration efficiency of NPs  and limits the  subsequent 
penetration depth. Unfortunately, this important fac-
tor is not present in many MTS studies. Therefore, a 
uniform in vitro tumor model comprising of both tu-
mor spheroids and a vascular endothelium is highly 
desired to study the extravasation and penetration of 
NPs for imaging and therapeutic purposes. 
Here, we report an in vitro uniform MTS system 
with vascular endothelium for the extravasation and 
penetration  studies  of  Fe3O4  NPs.  We  used  mi-
cromolded  non-adhesive  agarose  gels  [16]  to  con-
struct a uniform MTS coated with endothelial cells. 
Utilizing  the  micromold  and  self-assembly  tech-
niques, cell-cell sorting interactions formed a model 
for  a  tumor  core  that  must  be  accessed  through  a 
leaky  vasculature.  Rat  RG2  cells,  a  glioblastoma 
model cell line, formed a MTS core similar to that of a 
solid tumor, while bovine-pulmonary arterial endo-
thelial (BPAE) cells assembled on the surface of the 
MTS. The layer of endothelial cells restricted access to 
the tumor core and acted as the vascular endothelium. 
This technique formed hundreds of uniform replicates 
for the endothelium-coated tumor model in a single 
culture  well.  We  demonstrate  the  use  of  this 
three-dimensional  cell-culture  platform  with  Fe3O4 
NPs conjugated with  tumstatin peptide, a naturally 
occurring fragment of type IV collagen. Fe3O4 NPs are 
bio-compatible contrast agents for T2-based magnetic 
resonance imaging (MRI) [17], while tumstatin pep-
tide binds specifically to αvβ3 integrin on the endo-
thelial cells and can significantly inhibit endothelial 
cell  proliferation  [18].  A  component  of  basement 
membrane, tumstatin acts upon the mTOR pathway 
inhibiting  protein  synthesis  in  endothelial  cells.  We 
examine the active T7 fragment (74-98) of tumstatin 
(3020.85 dalton). The coupling of tumstatin onto Fe3O4 
NPs allowed the specific targeting to BPAE cells and 
inhibited the proliferation of these cells [19, 20]. The 
penetration depth of tumstatin-Fe3O4 NPs was visu-
alized and quantified by fluorescent confocal imaging 
and transmission electron microscope (TEM) imaging. 
Our results establish a uniform in vitro tumor model 
comprising  both  tumor  spheroid  and  endothelium 
that can be used for NP penetration studies. With the 
help of this model, we demonstrated the specific tar-
geting of tumstatin modified Fe3O4 NPs to endothe-
lium. We believe this work offers new opportunities 
for the study of NPs penetration. 
Materials and methods 
All  chemicals  and  solvents  except  mentioned 
specifically  were  of  analytical  grade  from  Sig-
ma-Aldrich  (St  Louis,  MO)  and  were  used  without 
further purification. MTS micro-molds were obtained 
from  MicroTissues,  Inc,  (Providence,  RI).  Tumstatin 
was  generously  donated  by  Dr.  Raghu  Kalluri.  Rat 
RG2  glioblastoma  cells  and  BPAE  cells  (CCL-209) 
were obtained from the American Type Culture Col-
lection (Rockville, MD). Both cells are maintained in 
Dulbecco's  modiﬁed  Eagle's  medium  (DMEM,  Invi-
trogen),  supplemented  with  10%  FBS  (Invitrogen), 
2mM  L-glutamine  (Invitrogen),  and  1%  Pen/Strep 
(Invitrogen).  Theranostics 2012, 2 
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Synthesis and modification of Fe3O4 NPs 
10 nm Fe3O4 NPs were synthesized through the 
high  temperature  decomposition  of  iron  (III)  acety-
lacetonate (Fe(acac)3) in a mixture of benzyl ether and 
oleylamine. The synthesized NPs were made hydro-
philic  and  functionalized  through  ligand  exchange 
with  dopamine  modified  polyethylene  glycol 
(DPA-PEG-COOH).  Detailed  methods  are  described 
in our previous publications [21]. 
Tumstatin labeling with rhodamine B isothiocy-
anate (Rhod) and subsequent coupling with 
Fe3O4 NPs  
Tumstatin was incubated with Rhod (Invitrogen) 
in Na2CO3/NaHCO3 (pH = 9) buffer at room temper-
ature for 1 hour (Tumstatin:Rhod = 1:10). The final 
conjugate  was  purified  by  removing  the  free  Rhod 
through the PD-10 desalting column (GE Healthcare 
Corp.).  Then,  Fe3O4  NPs  coated  with 
DPA-PEG-COOH  (100  µg)  were  activated  with 
ethyl(dimethylaminopropyl)  carbodiimide  (EDC) 
(100ng) and n-hydroxysuccinimide (NHS) (100 ng) in 
500 µL phosphate buffered saline (PBS). Then 100 µg 
tumstatin-Rhod in 100 µL PBS was mixed with Fe3O4 
NPs for 2 hours. Tumstatin coated Fe3O4 NPs were 
purified from free tumstatin through high speed cen-
trifugation (8000 rpm for 15 min). 
Characterization of tumstatin-Fe3O4 NPs 
 Tumstatin-Fe3O4  NPs  were  visualized  through 
Philips CM20 at 120kV. The hydrodynamic diameters 
of NPs were measured through Malvern Zeta Sizer 
S90. The conjugation of tumstatin onto Fe3O4 NPs was 
confirmed  through  infrared  spectroscopy  (IR)  by  a 
Bruker Tensor 27 FTIR. 
BPAE viability test with tumstatin-Fe3O4 NPs 
 BPAE  cells  were  seeded  in  96-well  plates  and 
incubated with NPs under various Fe concentrations 
for 24 hours. The viability was assessed through col-
orimetric cell viability assay (MTT assay). 
BPAE proliferation test with tumstatin-Fe3O4 
NPs  
200,000 BPAE cells were seeded in T25 flasks and 
incubated with NPs (in triplicate) under  Fe concen-
tration at 0.1 mg/ml. At 1, 3, 6, and 8 days, BPAE cells 
were trypsinized and counted. 
Tumstatin-Fe3O4 NPs uptake with BPAE and 
RG2 cells  
BPAE and RG2 cells were seeded in T25 flasks 
with 200,000 seeding density 24 hours before the ex-
periments. Then the medium was replaced with 1% 
FBS-containing  DMEM  supplemented  with  tum-
statin-Fe3O4 NPs or Fe3O4 NPs. After 4 hours incuba-
tion, the cells were washed with PBS twice and di-
gested  with  a  mixture  of  nitric  acid  and  hydrogen 
peroxide (3:1). Fe concentration was quantified with 
inductively  coupled  plasma  (ICP)  atomic  emission 
spectroscopy (Jobin Yvon JY2000). 
Preparation of BPAE coated RG2 MTS 
 Micromolds (MicroTissues, Inc) were prepared 
as previously described and were autoclave sterilized 
[16].  Autoclave-sterilized  powder  Ultrapure™  Aga-
rose (Invitrogen, Carlsbad, California) was dissolved 
with heating in sterile water to 2% w/v and pipetted 
into  the  micromolds.  After  setting,  micromolded 
agarose  gels  were  separated  from  the  mold,  trans-
ferred  to  six-well  tissue  culture  plates,  and  equili-
brated overnight in culture medium. To form MTS, 
RG2 and BPAE cells were trypsinized, counted, and 
re-suspended  to  500,000  cells  per  200  μL  of  culture 
medium  at  a  ratio  of  1:1  RG2:BPAE.  Medium  was 
removed from the tissue culture plates containing the 
micromolded hydrogels, and 200 μL cell suspension 
was added dropwise with a micropipette to the center 
of  the  seeding  chamber  of  each  gel.  Cells  were  al-
lowed to settle into the recesses for 30 min before 5 
mL of additional culture medium was carefully added 
to  the  medium  exchange  ports  of  the  micromolded 
gels. Cells self-assembled within 24 h at 37°C. MTS 
were maintained in the incubator and culture medium 
was changed every day. Side view microscopy was 
obtained as described in previous publications [22]. 
Live-cell fluorescent staining of MTS with tum-
statin-Fe3O4 visualized by confocal microscopy  
MTS were cultured in non-adhesive hydrogel for 
24  hours  and  were  incubated  with  culture  medium 
containing Rhod-labeled tumstatin-Fe3O4 NPs (0.1 mg 
Fe/mL) for 4 hours, and then washed twice with PBS. 
Fe3O4 NPs labeled with Rhod but without tumstatin 
were used as a control. MTS were visualized on 1 mi-
cron  cross-section  planes  by  confocal  microscope 
(Leica TCS SP2 AOBS spectral confocal microscope). 
The sorting of glioma and endothelial cell heter-
otypic microtissues were visualized with staining by 
fluorescent  dyes,  CellTracker  Red  CMTPX  and 
CellTracker  Green  CMFDA  (Invitrogen,  Carlsbad, 
California). Cells were loaded 1 day prior to seeding. 
Subconfluent  flasks  were  incubated  with  DMEM 
containing 2.5 µM CellTracker for 45 min at 37°C. Dye 
containing DMEM was then discarded and replaced 
with fresh culture medium. Stained cells were tryp-
sinized and seeded into hydrogels with a 1:1 ratio of 
endothelial  cell  and  glioma  cells.  CellTracker  Red 
CMTPX and CellTracker Green CMFDA were imaged Theranostics 2012, 2 
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by Leica TCS SP2 AOBS spectral confocal microscope 
(Leica, Wetzlar, Germany) or epi-fluorescent micros-
copy using a model (Olympus, Tokyo, Japan) with an 
excitation/detection of 577/602 nm and 492/517 nm, 
respectively. 
TEM preparation of MTS labeled with tum-
statin-Fe3O4 
 MTS were cultured in non-adhesive hydrogels 
for 24 hours and were incubated with culture medium 
containing Rhod-labeled tumstatin-Fe3O4 NPs (0.1 mg 
Fe/mL)  for  24  hours,  and  then  washed  twice  with 
PBS.  MTS  were  fixed  in  phosphate-buffered 
Karnofsky's solution and hydrogels were inverted to 
isolate MTS. Collected MTS were suspended in fixa-
tive for 30 minutes before they were spun down using 
centrifugation and fixative was aspirated. MTS were 
stained with 2% osmium tetroxide at 4ºC overnight, 
followed  by dehydration  using  graded  ethanol  and 
embedded in Epon 812 resin. Resin blocks were sec-
tioned using a microtome, doubly stained with uranyl 
acetate  and  lead  hydroxide,  and  imaged  on  TEM 
(Philips CM20 at 80kV). 
SEM preparation of MTS labeled with tum-
statin-Fe3O4 
 MTS were cultured in non-adhesive hydrogels 
for  24  hours  and  were  fixed  in  phosphate-buffered 
Karnofsky's  solution.  Hydrogels  were  inverted  to 
isolate MTS. Collected MTS were suspended in fixa-
tive for 30 minutes before they were spun down using 
centrifugation and fixative was aspirated. MTS were 
dehydrated using graded ethanol and transferred to 
the critical point drying apparatus for final substitu-
tion with liquid CO2. Dried MTS were placed on car-
bon adhesive SEM tabs and spin-coated for observa-
tion and imaging in SEM (Hitachi 2700).  
Spheroid immunostaining 
 MTS cultured in non-adhesive hydrogels for 24 
hours  were  fixed  in  phosphate-buffered  Karnofsky 
solution (2% paraformaldehyde, 2% glutaraldehyde). 
Gels  were  inverted  to  remove  MTS.  MTS  were 
washed  five  times  in  0.002%  Triton  X-100  in  phos-
phate buffered solution (PBS), and MTS were gently 
agitated for five minutes between washes. Cells in the 
MTS  were  then  permeablized  for  one  hour  in  0.5% 
Triton X-100 in PBS. MTS were washed twice in PBS, 
then blocked in 1% BSA for 20 minutes. 10 μL Oregon 
Green 488®-conjugated phalloidin (Invitrogen, Carls-
bad,  California)  in  MeOH  was  dissolved  in  400  μL 
PBS and incubated for 30 minutes. MTS were washed 
twice in PBS and blocked with 1% BSA and 4% goat 
serum. 2 mL of 20 µg/mL of primary antibody (mouse 
anti-occludin and rabbit anti-zonula occluden 1, Invi-
trogen, Carlsbad, California) in working solution (4% 
goat serum, 1% BSA, in PBS)  was added and incu-
bated 8 hours overnight at 4 ºC. Primary antibody was 
removed  and  blocking  solution  (working  solution, 
0.1%  Triton  in  PBS)  was  added  for  one  hour.  MTS 
were rinsed three times in one mL 20 µg/mL of PBS 
and  secondary  antibody  (Texas  Red-X  goat  an-
ti-mouse and Alexa Fluor 546 goat anti-rabbit, Invi-
trogen, Carlsbad, California) was added for 8 hours at 
4 degrees Celsius. MTS were then washed 3 times in 1 
mL  PBS  and  visualized  using  confocal  microscopy 
(Zeiss Observer Z1). 
Results  
To  study  Fe3O4  NP  penetration  into  MTS,  we 
first functionalized the 10 nm Fe3O4 NPs with tum-
statin.  Tumstatin  binds  to  αvβ3  integrin,  which  is 
highly expressed on the cell surface of proliferative, 
neovascular endothelial cells and in some cancerous 
cells [23]. This naturally occurring peptide has shown 
to significantly suppress endothelial cell proliferation 
in vitro by inhibiting protein synthesis [18], as a result 
of  its  action  on  anti-angiogenic  and  pro-apoptotic 
pathways. 
Preparation and characterization of tum-
statin-Fe3O4 NP  
Fe3O4 NPs were synthesized through high tem-
perature decomposition of Fe(acac)3, which allows for 
the  precise  control  of  particle  size  and  quality  that 
provides higher T2/T2* relaxivity properties[24]. The 
as-synthesized NPs were made water-soluble through 
ligand exchange with a synthesized DPA-PEG-COOH 
polymer accomplished via our previous protocol [21]. 
Tumstatin was modified with Rhod before conjuga-
tion with NPs to allow for quantification and fluores-
cent visualization. The conjugation of tumstatin onto 
Fe3O4 NPs was achieved through EDC-NHS coupling, 
which allows the conjugation of ~4 tumstatin mole-
cules on one single NP (quantified through fluores-
cence  intensity).  The  prepared  tumstatin-Fe3O4  NPs 
were dispersed in PBS and had a hydrodynamic di-
ameter of about 30 nm. Figure 1 shows the TEM im-
ages of the NPs before and after tumstatin coupling, 
from which we observed that surface treatments did 
not  change  the  NP  morphology.  The  presence  of 
tumstatin  on  Fe3O4  NPs  was  confirmed  through  IR 
(Supplementary Material: Fig. S1).  Tumstatin conju-
gation enhanced the uptake of Fe3O4 NPs by αvβ3 in-
tegrin-expressing  endothelial  cells,  BPAE  cells.  As 
shown Figure 2A, BPAE cells showed more than twice 
as  much  uptake  of  tumstatin-Fe3O4  NPs  compared 
with the more rapidly proliferating RG2 cells at 0.1 
mg Fe/mL media concentration. The slowly prolifer-Theranostics 2012, 2 
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ating  BPAE  cells  had  comparable  uptake  at  lower 
concentrations of 0.01 and 0.001 mg Fe/mL media.  
Both tumstatin-Fe3O4 NPs and Fe3O4 NPs were 
nontoxic to the cells studied as measured by the MTT 
viability assay under three concentrations (0.1, 0.01, 
and 0.001 mg Fe/mL) (Figure 2B). However, prolifer-
ation of BPAE cells was inhibited by tumstatin-Fe3O4 
NPs (0.1 mg Fe/mL) (Figure 2C) as expected, given 
that  tumstatin is  an inhibitor of endothelial cell 
proliferation. BPAE cell number remained relatively 
constant  after  8  days  of  culture  in  the  presence  of 
tumstatin-Fe3O4 NPs, whereas in the presence of con-
trol Fe3O4 NPs cell number increased by 2.7 times.  
 
 
Figure 1. (A) Fe3O4 particles as-synthesized and (B) after DPA-PEG-COOH modification and tumstatin conjugation imaged 
by TEM. 
 
 
 
 
Figure 2. (A) RG2 and BPAE cells uptake more particles at a higher concentration of tumstatin-Fe3O4 NP as measured by 
elemental analysis. (B) BPAE cell viability was not significantly affected by the addition of functionalized tumstatin-Fe3O4 
particles as compared to untargeted Fe3O4 NPs as measured by an MTT viability assay after 24-hours of incubation. (C) 
Proliferation of BPAE cells decreased when incubated with tumstatin-Fe3O4 NPs versus non-functionalized Fe3O4 NPs 
(Fe=0.1mg/ml). 
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Fabrication and characterization of endotheli-
al-coated MTS 
To  construct  the  endothelial-coated  MTS,  two 
main conditions needed to be satisfied: the formation 
of MTS core, and the selection of endothelial cell line 
for the construction of endothelium. 
Thus, we first identified the seeding conditions 
and growth trend of the single cell line RG2 MTS in 
our base microtissue design method (Supplementary 
Material: Fig. S2) [16]. Following the initial cell seed-
ing process, there were two stages in the formation of 
MTS:  cell  self-assembly  and  cell  growth.  The 
self-assembly occurred within 24 hours right after cell 
seeding. Once the cell suspension was added into the 
agarose hydrogel, monodisperse cells settled into the 
non-adhesive  wells,  formed  cell-cell  contacts,  and 
became 3D spheroids. The size of the MTS could be 
controlled by the seeding number of RG2 cells, thus 
increasing  the  number  of  cells  resulted  in  the  for-
mation of spheroids of larger diameter (Supplemen-
tary Material: Fig. S3A). For example, at the seeding 
density  of 822,000 cells per hydrogel, RG2 MTS as-
sembled at a diameter of 100µm. The MTS size was 
dispersed in a Gaussian distribution for each seeding 
density  (Supplementary  Material:  Fig.  S3B).  In  the 
following growth stage, the size of MTS increased as a 
result of RG2 cells proliferation that was revealed by 
the  measurement  of  metabolic  activity  (Supplemen-
tary Material: Fig. S4). 
After  the  identification  of  seeding  density  and 
growth pattern of the RG2 MTS (core), the next key 
question is to find a suitable endothelial cell line to 
develop the endothelium on RG2 MTS. We studied 
two endothelial cell lines, BPAE and human umbilical 
vein endothelial cells (HUVEC). Before seeding onto 
the agarose gels and to facilitate their identification, 
cells were labeled with fluorescent marker CellTrack-
er. BPAE or HUVEC cells are shown in blue while the 
MTS that were formed with RG2 cells are shown in 
green. 24 hours after cell seeding, BPAE cells assem-
bled  an  endothelium  layer  on  the  RG2  MTS,  while 
HUVEC did not coat the MTS. HUVEC cells formed 
an  independent  spheroid  adjacent  to  the  RG2  MTS 
(Supplementary Material: Fig. S5). The formation of 
an independent HUVEC spheroid instead of the for-
mation of an endothelium layer on the RG2 MTS is 
probably  due  to  stronger  HUVEC-to-HUVEC  cell 
interaction  as  opposed  to  HUVEC-to-RG2  interac-
tions. The importance of cell line selection was also 
seen when we tested MTS formed from 9L cells, an-
other glioma cell line. BPAE cells mixed with the 9L 
cells indiscriminately whereas HUVEC formed small 
aggregates on the 9L MTS (Supplementary Material: 
Fig. S5). Although greater versatility with more cell 
lines  is  desirable,  cell-cell  interactions  dominate  the 
formation of microtissue structures [23]. Tissue engi-
neering and microtissue formation are continuously 
being studied to gain greater understanding and ob-
tain greater control. The endothelial cell-coated glio-
ma is a novel microtissue of interest. 
After addressing the above two key components, 
we focused on the RG2 and BPAE model for the re-
mainder of this study due to the desirable endothelial 
cell-coated glioma MTS formation. Figure 3A shows a 
smooth  RG2  MTS  as  compared  to  the  cobblestone 
morphology of BPAE cells when grown individually; 
the co-culture of BPAE and RG2 cells show a blend 
between the two structures of a cobblestone surface 
with smooth core when cultured together. BPAE cells 
preferentially  coat  the  outside  of  the  RG2  core  be-
coming  a  tumor  core  with  an  endothelial  cell  shell 
after 24 hours of self-assembly (Figure 3B&C). The use 
of  non-adhesive,  micromolded  wells  enabled  the 
generation of large numbers of uniform sized sphe-
roids.  To  examine  their  structure  in  more  detail, 
BPAE-coated  RG2  MTS  were  examined  using  fluo-
rescent,  confocal,  and  SEM  after  24-hour  of 
self-assembly. As revealed through Figure 3D, BPAE 
cells  began  to  form  a  coating  of  1-3  rounded,  cob-
ble-stone endothelial cells (resembling that of a leaky 
vasculature network) on top of a smooth RG2 core. As 
a  marker  for  endothelium  formation,  tight  junction 
markers  of  zona  occludens  1  (ZO-1)  and  occludin 
were  identified  by  immuno-staining  and  were  ob-
served to co-localize at BPAE cell-cell contacts (Sup-
plementary  Material:  Fig.  S6).  Actin  cytoskeleton 
staining co-localized to the cell-cell contacts and cor-
related with the tight junction contacts. 
To quantify the extent of endothelial coating and 
determine the length of time the coating persisted on 
the  RG2  MTS,  we  used  image  analysis  of  confocal 
images to measure the amount of continuous endo-
thelial  perimeter.  The  MTS  had  an  endothelial 
cell-coating with approximately 90% and 85% cover-
age  for  days  1  and  2,  respectively,  after  assembly 
(Supplementary Material: Fig. S7). Although coverage 
was not complete, the 1-3 layers of endothelial cells on 
the surface created a tortuous network in the endo-
thelial cell coating. On day 3, endothelial cell coverage 
decreased to approximately 60% due to the prolifera-
tion of the RG2 cells.  
Penetration study of tumstatin-Fe3O4 NPs of 
endothelium-coated MTS 
The BPAE-coated RG2 MTS were incubated with 
tumstatin-Fe3O4  NPs  (0.1  µg  Fe/mL)  for  4  hours. 
Fe3O4 NPs labeled with Rhod and not conjugated with Theranostics 2012, 2 
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tumstatin  were  used  as  a  control  (Supplementary 
Material: Fig. S8). After washing with PBS to remove 
the unattached NPs, MTS were examined with con-
focal  fluorescence  microscopy.  As  shown  in  Figure 
4A, the tumstatin-Fe3O4 NPs (red) co-localized with 
the BPAE cells (blue) in the top left and bottom left 
panel, respectively. A close-up view of the interface 
between BPAE and RG2 MTS (Figure 4B) confirmed 
that  tumstatin-Fe3O4  NPs  preferably  bound  onto 
BPAE cells even though some RG2 cells were adjacent 
to  BPAE  cells  (yellow  arrow  in  Figure  3D  bottom). 
This  specific  binding  indicates  that  tumstatin-Fe3O4 
NPs could act as both a targeting agent to endothe-
lium and a diagnostic to examine tumor vasculariza-
tion with the help of MRI. Further studies are under 
way to help assess this possibility. 
The  BPAE-RG2  MTS  labeled  with  tum-
statin-Fe3O4 NPs  were further examined with TEM. 
Given that there was a BPAE coating on the RG2 core 
(Figure 5A), we identified the interface between the 
coating and the core by the different morphologies of 
the BPAE cells and the RG2 cells (Figure 5B). In BPAE 
cells, the close-up TEM view revealed the presence of 
tumstatin-Fe3O4 NPs in cell endosomes and the cyto-
plasm  (Figure  5C&D).  However,  very  few  tum-
statin-Fe3O4 were observed in the core RG2 cells un-
der TEM (Supplementary Material: Fig. S9). This ob-
servation combined with the confocal imaging results 
described  above  (Figure  4A)  indicated  endothelial 
cells limited and even blocked NPs from penetrating 
into  the  microtissue,  which  is  similar  to  the  tumor 
environment  in  vivo.  Supported  by  this  conclusion, 
Tumstatin-Fe3O4 should be a great candidate for tar-
geting tumor vasculature with potential challenges in 
penetrating  into  the  tumor  mass.  To  improve  the 
penetration of NPs through the endothelium coating 
and into the MTS, a higher concentration and smaller 
hydrodynamic size could potentially be utilized. 
 
 
 
Figure 3. (A) Top-view bright field and custom side-view microscopic images of RG2 and BPAE spheroids with distinct 
smooth, compact and round, cobblestone morphology (scale bar = 200 m). (B) Epifluorescence images of BPAE-RG2 MTS 
in agarose micro-wells show an inital mixed dispersion settling during initial assembly stage and sort to a BPAE-coated RG2 
core 24 hours after cell seeding (scale bar = 200 m). (C) Fluorescent confocal cross-section view of BPAE coverage on RG2 
core after 24 hours of assembly. (D) SEM images of BPAE-RG2 MTS having BPAE cells grafted on RG2 cells. Theranostics 2012, 2 
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Figure 4: Tumstatin-Fe3O4 NPs (red) selectively target BPAE endothelial cells (blue) in the heterogeneous culture with RG2 
glioma cells (green). Median section of BPAE-RG2 spheroids were imaged with confocal microscopy (A). Greater magni-
fication shows cell specificity (B) and an overlay of confocal images shows co-localization throughout the spheroid. Yellow 
arrow points to one RG2 cell surrounded by the BPAE cells, where BPAE cells showed fluoresce from tumstatin-Fe3O4 NPs 
but RG2 cell didn’t. 
 
Figure 5. TEM examination of MTS labeled with Tumstatin-Fe3O4 NPs. (A) Illustration of the MTS structure; (B) image of 
the interface between RG2 core and BPAE shell; (C, 2 micron scale bar, and D, 1 micron scale bar) close examination of 
Tumstatin-Fe3O4 NPs in the endosome and cytoplasm of one BPAE cell (NPs denoted by arrows). Theranostics 2012, 2 
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Discussion 
Herein,  we  provided  a  more  thorough  in vitro 
model examining the penetration ability of NPs into a 
tumor mass, with the aim to provide greater resolu-
tion of early detection and drug delivery. In conceiv-
ing and testing this model, two criteria guided us: the 
in vitro model should be similar to the in vivo micro-
environment, but easy to reproduce and convenient 
for analysis; the NP system should be widely accepted 
in cancer research. 
Compared  with  the  conventional  models,  our 
endothelial-coated MTS model provides a facile and 
inexpensive  platform  between  in  vitro 
two-dimensional cell culture and the more laborious, 
complex and expensive animal model. The character-
ization of NPs in this three-dimensional in vitro model 
can  be  easily  performed  to  examine  the  next  incre-
mental step before going into a more elaborate study. 
This model can determine the ability to penetrate a 
leaky  tumor  vasculature  by  diffusive  properties  in 
biological  media  before  the  complex  interactions  of 
inflammation  and  immune  responses.  Further  de-
velopment of this 3D microtissue model and addition 
of  properties  that  more  mimic  the  in vivo  environ-
ment could help examine NPs and other theranostic 
agents in  greater detail before applying them to an 
animal model. However, due to the simplicity, com-
pared  with  the  in vivo  model,  systemic  interactions 
could  not  be  examined  such  as  pharmacokinet-
ics/pharmacodynamics of NPs and also the influence 
of inflammatory phagocytes (tumor associated mac-
rophages).  Thus  after  utilizing  our  model  to  screen 
NPs, the more promising agents should be tested in 
vivo for the collection of such information. 
Fe3O4 NPs are one of the most widely used NPs 
that are clinically safe and able to act as both imaging 
contrast agents and therapeutics. Tumstatin has been 
studied for its anti-angiogenic effects and mechanistic 
pathways have been elucidated. The in vitro test with 
cell  culture  confirmed  that  the  conjugation  of  tum-
statin onto Fe3O4 NP had similar therapeutic effect, 
but more importantly for our application, the ability 
to target endothelial cells. The ability for NP penetra-
tion into a tumor with leaky vasculature is tested and 
examined  using  the  3D  in  vitro  model.  Tum-
statin-Fe3O4  NP  demonstrates  this  application  by 
providing selective targeting to the leaky tumor vas-
culature with few NPs present in the tumor core. The 
increased amounts of tumstatin-Fe3O4 NPs associated 
with  the  leaky  vasculature  is  due  to  the  affinity  of 
tumstatin to the newly forming endothelial cell αvβ3 
integrins. In addition to this targeting, the 1-3 endo-
thelial cell layer coverage has begun to form an en-
dothelial layer creating a torturous path similar to that 
found in porous media. This structure effectively in-
creases endothelium surface area and decreases dif-
fusion of nanoparticles as described by basic material 
properties of porous media and independently con-
ducted diffusion studies (not shown). With 90% cov-
erage at day 1, the 10% of non-coverage is from patent 
and  non-patent  network  of  tortuous  channels.  The 
newly forming endothelium has the formation of tight 
junctions  at  endothelial  cell  contacts,  but  still  has 
pores and channels on the endothelial cell layer, sim-
ilar  to  that  seen  in  neovascularization.  Tum-
statin-Fe3O4 NPs’ affinity to vasculature could pro-
vide both diagnostic contrast of tumor vasculature in 
vivo and offer anti-angiogenic properties as shown in 
conventional cell culture. Greater methods are being 
developed  to  study  anti-angiogenic  effects  in  the 
three-dimensional model. 
In summary, we have developed and character-
ized a 3D in vitro platform to study the penetration of 
NPs  into  tumors.  By  utilizing  micromolded  nonad-
hesive  hydrogels,  we  have  developed  a  platform 
composed of a multi-cellular tumor spheroid coated 
with  an  endothelium  layer.  The  tumor  spheroid 
mimics the solid tumor while the endothelium coating 
represents the endothelium of the blood vessel, a sig-
nificant  barrier  to  the  delivery  of  therapeutics.  The 
platform  was  tested  with  a  model  NP,  tum-
statin-Fe3O4 NPs that preferentially binds to endothe-
lial cells and inhibits their proliferation. The results 
showed  that  tumstatin-Fe3O4  NPs  could  specifically 
target  to  the  endothelial  cells  in  a  complex  3D  mi-
crotissue  environment.  This  model  has  significant 
potential to help in the testing and optimization of the 
design  of  therapeutic/diagnostic  nanocarriers  and 
determine their therapeutic capabilities. 
Supplementary Material 
Fig. S1–S9. http://www.thno.org/v02p0066s1.pdf 
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